Skip to main content
. Author manuscript; available in PMC: 2022 Apr 7.
Published in final edited form as: Adv Exp Med Biol. 2021;1322:115–138. doi: 10.1007/978-981-16-0267-2_5

Table 5.14.

Drugs with other mechanisms in development

Drug Route Mechanisms Company Clinical trial phase ClinicalTrials.gov identifier
Lenvervimab (GC1102) IV Monoclonal antibody Green Cross, South Korea 2a NCT03801798/NCT02304315
Vonafexor (EYP001) Oral FXR agonist Enyo Pharma, France 1 NCT04365933
ASC22 (KN035) SC PD-L1 pathway Ascletis Pharma, PR China 2a NCT04465890
LTCR-H2–1 IV T cell immunotherapy Lion TCR, Singapore 1 NCT04745403

IV intravenous, SC subcutaneous, N/A not applicable